Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.68%
#4 Black Phoenix Black Phoenix +336.08%
#5 aPriori aPriori +112.62%
#6 Bedrock Bedrock +74.62%
#7 Cysic Cysic +47.27%
#8 Prom Prom +41.40%
#9 Playnance Playnance +34.98%
#10 COTI COTI +31.11%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Alseres Pharmaceuticals, Inc. Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc.

ALSE
Rank in Stocks #42806
Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and... Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia. Founded in 1972, the company was previously known as Boston Life Sciences, Inc. before officially changing its name to Alseres Pharmaceuticals, Inc. in June 2007. Its operations are headquartered in Auburndale, Massachusetts.
Share Price
$0.01
Last synced: 2024-08-19
Market Cap
$61.27
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alseres Pharmaceuticals, Inc. (ALSE)

Category

Healthcare
Revenue for Alseres Pharmaceuticals, Inc. (ALSE)
Revenue in Aug 2026 TTM: 0
According to Alseres Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alseres Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR